A total of some 30,000 people in the U.S. and Mexico, 44 per cent non-white, participated in the trial. The vaccine was 90.4 per cent effective in those with symptoms of COVID-19 and 100 per cent successful in moderate and severe cases.
Novavax is not just another vaccine. Its strategy is different from those used so far. For instance, Moderna’s mRNA vaccine directs the cell to make a surface protein found in the SARSCOVID-2 and then instruct the body’s immune system to rise against it. Instead, Novavax delivers the entire spike protein into the body using nanotechnology. This is called protein technology, found effective against Hepatitis-B.
The new two-shot vaccine (NVX-CoV2373) is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the UK and South Africa variants
Another advantage is that Novavax does not need ultra cold....
